<prompt> AML with FLT-3 mutation is treated by :CrizotinibGilteritinibAcalabrutinibIbrutinib  <response>: Gilteritinib inhibits FMS like tyrosine Kinase 3 FLT-3 and hence used in the treatment of AML with FLT-3 mutation. 